Recruiting Kidney Cancer Studies in Dallas
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
This phase II trial tests whether using genetic testing of tumor tissue to select the optimal treatment regimen works in treating patients with clear cell renal cell (kidney) cancer that has spread to...
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
To learn if giving tivozanib in combination with nivolumab can help to control advanced nccRCC....
About Kidney Cancer Clinical Trials in Dallas
Kidney cancer, most commonly renal cell carcinoma, develops in the lining of the kidney tubules. It accounts for about 3-5% of all adult cancers. Treatment includes surgery, targeted therapy, immunotherapy, and radiation.
There are currently 2 kidney cancer clinical trials recruiting participants in Dallas, TX. These studies are seeking a combined 102 participants. Research is being sponsored by Vanderbilt-Ingram Cancer Center, M.D. Anderson Cancer Center. Clinical trial participation is free and participants receive study-related medical care at no cost.
Kidney Cancer Clinical Trials in Dallas — FAQ
Are there kidney cancer clinical trials in Dallas?
Yes, there are 2 kidney cancer clinical trials currently recruiting in Dallas, TX. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Dallas?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Dallas research site will contact you about next steps.
Are clinical trials in Dallas free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Dallas studies also compensate for your time and travel.
What kidney cancer treatments are being tested?
The 2 active trials in Dallas are testing new therapies including novel drugs, biologics, and treatment approaches for kidney cancer.
Data updated March 2, 2026 from ClinicalTrials.gov